29
May
2025
GSK Antibiotic Hits, ORIC Prostate Cancer Drug Shines, & Taysha Goes 10-for-10
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
28
May
2025
5 East Asian Americans in Biopharma on Pivotal Moments in Their Immigration Story
They called it Gold Mountain. For Chinese in the 19th century, the “gold mountains” of California and North America represented the promise of success and upward mobility. It was their name for the American Dream. And at a time when America’s appeal to dreamers and strivers around the world is under strain, it’s worthwhile to reflect on the incredible paths... Read More
28
May
2025
A New and Old Idea for Cardiovascular Disease & Diabetes: Ethan Weiss & Josh Lehrer on The Long Run
Ethan Weiss and Josh Lehrer are today’s guests on The Long Run. Ethan is the co-founder and chief scientific officer of South San Francisco-based Marea Biosciences. Josh is the CEO. They are seeking to blaze a new trail with a drug to reduce the risk of cardiovascular disease and type 2 diabetes. It’s a monoclonal antibody aimed at ANGPTL4. There... Read More
27
May
2025
GlycoEra Grabs $130M to Develop Extracellular Degraders for Autoimmunity
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
27
May
2025
Reclaiming Biotech’s Edge: In Defense of Taking Disciplined Risk
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
22
May
2025
Vigil, Inozyme Acquired, Prime Cuts, & Regeneron Scoops Up 23andMe
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
15
May
2025
Genentech’s Bet on NC, GSK Buys Boston Liver Drug, & Septerna Entices Novo
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
13
May
2025
Biologic Drug Discovery Made Faster: Peyton Greenside on The Long Run
Peyton Greenside is today’s guest on The Long Run. Peyton is the co-founder and CEO of San Mateo, Calif.-based BigHat Biosciences. The company was started in 2019 to build on advances in synthetic biology and machine learning to design antibody drugs with a variety of different properties, faster. The company has gone on to raise more than $100 million in... Read More
8
May
2025
Health Deserves A Vision More Capacious Than Dashboard Metrics
Consumer health and wellness is experiencing a flurry of activity. The lab testing company Function (motto: “It’s time to own your health”) acquired Ezra, a whole body MRI company promising “the world’s most advanced longevity scan.” Oura, maker of the popular smart ring, recently added an integration for continuous glucose measurement as well as the ability to calculate meal... Read More
8
May
2025
NewLimit’s Anti-Aging Bounty, a Twist Spinout, & AI Coming to the FDA
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
4
May
2025
Tech-Enabled Power To The People: Ingratiating Chatbots and a Virtuous Food App
For at least a decade, nearly every tech company has promoted their product as facilitating the “democratization” of something – perhaps “data driven medicine,” or “genetic information” or “access to clinical trials” or “digital health” (all real examples). Like “mission-driven,” “results-oriented,” and “disruptive,” the term “democratization” has become so overused by the tech community that it’s now more of an... Read More
3
May
2025
Our Collective Hope For AI in Health, Plus Explanatory Models and an Epic Podcast
A recent piece by Nathan Price captures our collective hope for AI in health with unusual clarity, even as there remains impassioned disagreement regarding how close these ambitions are to meaningful realization. For context, Price is Professor and Co-Director of the Center for Human Healthspan at the Buck Institute for Research on Aging and CSO of Thorne, a company best... Read More
2
May
2025
A Sublime Experience: Views of Timmerman Traverse for Damon Runyon Cancer Research
Kathmandu, Nepal We did it together. The Timmerman Traverse for Damon Runyon Cancer Research Foundation completed a splendid expedition to Everest Base Camp on Apr. 23, 2025. This trip succeeded on every count. All 17 members of the team made it to the mountaineering camp at 17,600 feet / 5,364 meters. We exceeded our $700,000 fundraising goal for high-risk /... Read More
22
Apr
2025
Embracing Non-Linear Career Paths: Professor Martin Gaynor
(Guest) Editor Note: Martin Gaynor, the Lester A. Hamburg University Professor of Economics and Public Policy at Carnegie Mellon University, was recently honored with the Victor R. Fuchs Award for Lifetime Contributions to the Field of Health Economics by the American Society of Health Economists. His response (shared with his permission) was both striking and magnificent, emphasizing the contingency of... Read More
22
Apr
2025
The Four Dysfunctions of Corporate Cultures—Applied to Biopharma
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
14
Apr
2025
Can You Improve Your Health Without Obsessing About It?
Can you improve your health without obsessing about it? I’ve been, well, obsessing about this question as I continue to spend more time and mindshare in the world of healthy aging evangelists, enthusiasts, and entrepreneurs, longevity champions keen to guide you, and often test you, towards their conceptions of healthier aging. (See this piece on the longevity boom, and this... Read More
14
Apr
2025
Finding New Targets for Cancer Drugs: Kevin Parker on The Long Run
Kevin Parker is today’s guest on The Long Run. Kevin is the co-founder and CEO of South San Francisco-based Cartography Biosciences. The company is using multi-omic tools to map out which targets are specifically expressed on cancer cells. The idea is to find new, precise targets that antibody drugs can aim for. Cartography got started during the pandemic, raised a... Read More
11
Apr
2025
Why I Left European Science
Monday was my last day as a group leader at The Francis Crick Institute. I got my job at the Crick in 2020, almost exactly 5 years ago, right as COVID was beginning. I had finished my PhD in 2019, and had always told myself that I would only ever be an academic if I could find a place where... Read More
10
Apr
2025
FDA in Crisis, Parker Institute Snags Big Fish, & Merida Megaround
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
9
Apr
2025
What US Biotech Can Do to Meet the Moment
We have entered a new era in biotech. Turmoil at the FDA has introduced new uncertainty. NIH funding cuts and grant delays have led to academic institutions to hold off on job offers to young scientists. The Trump Administration’s reset of trade relations with the world caused a financial market meltdown, and wild rebound. All of these things are... Read More